Market Overview

Morning Market Losers

Share:
Related FNSR
Daily Movers: AirMedia Soars; Uranium Energy Under Investigation
Raymond James Downgrades Finisar To Outperform
Related OMED
OncoMed Reports Presentation of Phase 1b Trial for Tarextumab in Small Cell Lung Cancer at ASCO
OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer

Finisar (NASDAQ: FNSR) shares tumbled 23.56% to $19.30 after the company reported downbeat earnings for the fourth quarter and issued a weak profit forecast for the current quarter.

OncoMed Pharmaceuticals (NASDAQ: OMED) dropped 20.64% to $19.76 after the company voluntarily stopped enrollment for Phase 1 Vantictumab.

Cesca Therapeutics (NASDAQ: KOOL) declined 16.39% to $1.48 after the company priced priced 7.53 million share offering at $1.55 per share.

Oculus Innovative Sciences (NASDAQ: OCLS) fell 7.29% to $3.05 on Q4 results. The company's net income rose $9.9 million to $7.5 million in the quarter.

TG Therapeutics (NASDAQ: TGTX) shares declined 7.26% to $8.18 after the company's TG-1101 in combination with Ibrutinib showed a 90% response rate in patients with previously treated CLL and MCL.

Achillion Pharmaceuticals (NASDAQ: ACHN) dropped 4.10% to $6.55 after dropping 6.32% on Thursday.

Posted-In: market losersNews Movers & Shakers Intraday Update Markets

 

Related Articles (ACHN + FNSR)

Get Benzinga's Newsletters